Barclays began coverage on shares of PRA Health Sciences (NASDAQ:PRAH) in a research report report published on Monday morning. The brokerage issued an overweight rating and a $94.00 target price on the medical research company’s stock.

A number of other equities analysts have also recently issued reports on PRAH. Robert W. Baird set a $94.00 price objective on PRA Health Sciences and gave the company a buy rating in a report on Friday, December 1st. Mizuho began coverage on PRA Health Sciences in a report on Thursday, September 21st. They set a buy rating and a $82.00 price objective for the company. Raymond James Financial began coverage on PRA Health Sciences in a report on Wednesday, August 16th. They set an outperform rating and a $89.00 price objective for the company. Zacks Investment Research upgraded PRA Health Sciences from a hold rating to a buy rating and set a $83.00 price objective for the company in a report on Tuesday, September 19th. Finally, KeyCorp restated a buy rating and set a $93.00 price objective (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. PRA Health Sciences currently has an average rating of Buy and an average target price of $89.50.

PRA Health Sciences (NASDAQ PRAH) traded up $1.04 during midday trading on Monday, hitting $83.75. The stock had a trading volume of 503,400 shares, compared to its average volume of 526,221. The company has a market cap of $5,241.31, a P/E ratio of 30.41, a P/E/G ratio of 1.43 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. PRA Health Sciences has a 52-week low of $53.47 and a 52-week high of $84.38.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The firm had revenue of $494.55 million for the quarter, compared to the consensus estimate of $477.89 million. During the same quarter in the previous year, the company posted $0.64 EPS. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. research analysts expect that PRA Health Sciences will post 3.2 EPS for the current fiscal year.

In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of PRAH. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares during the period. Carroll Financial Associates Inc. raised its position in shares of PRA Health Sciences by 127.4% in the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after acquiring an additional 790 shares in the last quarter. Comerica Bank bought a new position in shares of PRA Health Sciences in the 3rd quarter worth $214,000. Trustmark National Bank Trust Department bought a new position in shares of PRA Health Sciences in the 2nd quarter worth $225,000. Finally, Aperio Group LLC bought a new position in shares of PRA Health Sciences in the 2nd quarter worth $233,000. Institutional investors and hedge funds own 98.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/12/12/pra-health-sciences-prah-now-covered-by-analysts-at-barclays.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.